Generic Name and Formulations:
Methylphenidate 10mg, 15mg, 20mg, 30mg; delivered over 9hrs; transdermal patches.
Indications for DAYTRANA:
Attention deficit hyperactivity disorder.
<6yrs: not established. 6–17yrs: Initially apply one 10mg patch to hip 2hrs before desired effect, remove 9hrs after application; may remove earlier if shorter duration of effect or late day side effects appear. May titrate dose at 1-week intervals. Reevaluate periodically. Rotate application sites.
Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family. During or within 14 days of MAOIs.
History of drug dependence or alcoholism; monitor for abnormal behavior. Discontinue if contact sensitization is suspected; may develop systemic sensitization with other MPH formulations (see full labeling). Avoid exposing patch to direct external heat sources. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. History of vitiligo. Monitor for signs of skin depigmentation; discontinue if chemical leukoderma develops. Monitor growth, BP, HR, CBCs, differential, platelet counts. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Hypertensive crisis with MAOIs. May potentiate coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), tricyclics (eg, imipramine, clomipramine, desipramine), SSRIs. May decrease effectiveness of antihypertensive agents. Caution with pressor agents. Risk of serotonin syndrome with serotonergic drugs.
Application site reactions (eg, erythema), decreased appetite, insomnia, nausea, vomiting, weight loss, tics, affect lability, anorexia, dizziness, abdominal pain, headache, irritability; priapism, hypertension, tachycardia, visual disturbances.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)